Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.10
0.00 (0.00%)
At close: Jan 23, 2026

HKG:3378 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Other Revenue
2.22.54
2.22.54
Revenue Growth (YoY)
-13.39%-
Gross Profit
2.22.54
Selling, General & Admin
46.1917.22
Research & Development
74.7246.66
Operating Expenses
120.9163.88
Operating Income
-118.71-61.34
Interest Expense
-9.38-2.28
Interest & Investment Income
2.924.13
Currency Exchange Gain (Loss)
0.94-
EBT Excluding Unusual Items
-124.23-59.5
Gain (Loss) on Sale of Investments
1.41-33.92
Pretax Income
-122.82-93.42
Income Tax Expense
-5.9-8.26
Earnings From Continuing Operations
-116.92-85.16
Minority Interest in Earnings
1.099.1
Net Income
-115.83-76.06
Net Income to Common
-115.83-76.06
Shares Outstanding (Basic)
117
Shares Outstanding (Diluted)
117
Shares Change (YoY)
49.83%-
EPS (Basic)
-10.60-10.42
EPS (Diluted)
-10.60-10.42
Free Cash Flow
-111.1-56.23
Free Cash Flow Per Share
-10.16-7.71
Gross Margin
100.00%100.00%
Operating Margin
-5398.55%-2416.07%
Profit Margin
-5267.39%-2995.51%
Free Cash Flow Margin
-5052.48%-2214.49%
EBITDA
-116.7-60.83
D&A For EBITDA
2.020.52
EBIT
-118.71-61.34
Source: S&P Global Market Intelligence. Standard template. Financial Sources.